Corion Biotech

Corion Biotech is a private, preclinical-stage biotech company founded in 2012 as a spin-off from the University of Turin. It is developing a novel 'Cell Therapy without Cells' platform derived from placental cells, with initial programs targeting preeclampsia and epithelial cancers (ovarian/breast). The company has achieved key regulatory milestones, including Orphan Drug Designation from the EMA for its preeclampsia candidate and positive FDA feedback, and has secured a GMP manufacturing partnership for clinical supply.

"Cell Therapy without Cells" platform using the therapeutic secretome/paracrine factors of Placental Mesenchymal Stromal Cells (hPDMSCs) to avoid direct administration of living cells.

In preeclampsia, direct drug competition is limited, but other research entities are exploring related pathways. In epithelial cancers, the competitive field is vast and includes numerous large pharma and biotech companies developing novel oncology therapies, making differentiation and demonstration of superior efficacy critical.